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Conclusion
So where do we stand today? We now
appreciate that CX3CR1 and presum-
ably fractalkine are important players
in atherogenesis, and that CX3CR1
contains polymorphisms that modu-
late its adhesive and signaling func-
tions and are associated with reduced
risk of atherosclerotic cardiovascular
disease. But to truly understand the
mechanism of CX3CR1 and other
genes in a highly complex and chronic
disease process such as atherosclerosis,
new practical intermediate markers are
required in both experimental models
and clinical studies.
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It has long been known that estrogen
deficiency in animal models and post-
menopausal women is associated with
increased osteoclastic bone resorption
and bone loss (1–5). In the past decade,
several important discoveries of some
of the key factors involved in osteoclast
formation, survival, function, and reg-
ulation by estrogen have been made.
A number of hormones and cytokines
modulate osteoclastogenesis by enhanc-
ing osteoclast differentiation, activation,
lifespan, and function. These include
parathyroid hormone (PTH), calcitriol,
PTH-related protein, prostaglandin E2,
thyroxine, and IL-11 (3–5). The forma-
tion of active osteoclasts requires 
M-CSF (1, 3–6) and involves cell-to-cell
contact between precursors of the mo-
nocyte/macrophage lineage and osteo-
blasts, marrow stromal cells, and T and
B cells. These cells express the receptor
activator of NF-κB ligand (RANKL), a
member of the TNF ligand family,
which is essential for this process.
RANKL attaches to RANK, a receptor
on the cell surface of osteoclasts and
osteoclast precursors, to stimulate pro-
liferation and differentiation of cells to
form the osteoclast phenotype and inhib-
it apoptosis. Osteoprotegerin (OPG), a
soluble decoy receptor produced by
osteoblasts, marrow stromal cells, and
other cells, profoundly modifies the
effects of RANKL by inhibiting RANKL/
RANK interaction (1, 3–5).
In laboratory animals, estrogen defi-
ciency leads to increased osteoclasto-
genesis and bone loss, and inhibition
of osteoclastogenesis is the major
means by which estrogen prevents the
loss of bone. This is accomplished by
diminishing production of IL-1, IL-6,
and TNF-α — cytokines that enhance
production of M-CSF and RANKL (1,
3–5) — and downregulating NF-κB and
RANKL-induced activation of JNK1
and osteoclastogenic activator pro-
tein–1 transcription factors c-Fos and
c-Jun (7). Estrogen upregulates OPG
(8) and TGF-β (9), and TGF-β increas-
es OPG expression by osteoblasts and
stromal cells (10) and inhibits bone
resorption by increasing apoptosis of
osteoclasts (11) (Figure 1).
RANKL and postmenopausal 
bone loss
Whether the OPG/RANKL/RANK sys-
tem is involved in bone loss caused by
estrogen deficiency in humans was not
known until now. In this issue of the JCI
(12), Eghbali-Fatourechi and colleagues
employ an elegant set of experiments to
examine the possible role of RANKL in
postmenopausal bone loss. The authors
obtained bone marrow mononuclear
cells and used surface markers and flow
cytometry to isolate and identify pre-
osteoblastic marrow stromal cells, T
lymphocytes, and B lymphocytes in
groups of premenopausal women,
untreated postmenopausal women, and
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postmenopausal women treated with
estrogen. Characteristically, serum
17β-estradiol was reduced, and serum
and urinary markers of bone resorption
were increased in postmenopausal com-
pared to premenopausal women and
postmenopausal women treated with
estrogen. Concentrations of serum OPG
and RANKL were not different in the
three groups. It was found that the levels
of RANKL per cell, preosteoblasts, T
cells, and B cells were increased by two-
to three-fold in the untreated postmeno-
pausal women and correlated positively
with serum and urinary markers of bone
resorption and negatively with serum
17β-estradiol in the three groups. As dis-
cussed in this article, the fact that serum
RANKL was not different in the three
groups indicates the necessity for inves-
tigating its concentration in the micro-
environment of marrow. These results
are important because they provide
strong evidence that: (i) it is the upregu-
lation of RANKL on bone marrow cells
as opposed to increases in the number of
T or B cells (as occurs in rodents) that
plays a pathogenetic role in increased
postmenopausal skeletal remodeling; (ii)
the immune system is intimately
involved in this process; and (iii) estro-
gen directly or indirectly modifies this
process. The study also provides a ration-
ale for the use of drugs that modify
osteoclastogenesis in the treatment of
estrogen deficiency–related bone loss.
Effects of OPG and RANK 
gene mutations
The importance of the OPG/RANKL/
RANK system in regulating osteoclasto-
genesis is underscored by the findings
that OPG-deficient mice develop pro-
found osteoclastogenesis and osteo-
porosis with fractures (13), and that
mutations in OPG and RANK in
humans cause unrestrained bone re-
sorption and generalized bone disease.
Inactivating mutations in TNFRSF11B,
the TNF receptor superfamily member
11b gene encoding OPG, causes a high
turnover bone disorder variously called
hereditary hyperphosphatasia, hyperos-
tosis corticalis deformans juvenilis,
craniotubular dysostosis with hyper-
phosphatasia, or juvenile Paget’s disease
(14,15). The disorder is characterized by
increased susceptibility to fractures,
marked increases in skeletal remodeling
with widened diaphyses and progressive
deformities of long bones, deformities
of the pelvis and vertebrae, and massive
thickening of the calvarium. Histologi-
cally, the number of osteoclasts and
osteoblasts is greatly increased. Activat-
ing mutations in TNFRSF11A, the TNF
receptor superfamily member 11a gene
encoding RANK, causes two bone dis-
eases. These are familial expansile oste-
olysis, which is characterized by focal
expansile osteolytic bone lesions and
generalized osteopenia (16), and expan-
sile skeletal hyperphosphatasia, which is
characterized by deafness, premature
loss of teeth, progressive hyperostotic
widening of long bones, enhanced bone
remodeling, and intermittent hypercal-
cemia (17). Since OPG has been shown
to reverse the bone disease in OPG-defi-
cient mice (18), OPG should be a made-




To date, drugs and hormones that act
by inhibiting osteoclast-mediated bone
resorption have been the mainstay of
osteoporosis treatment and prevention
of fractures. In addition to estrogen,
these  include bisphophonates, selective
estrogen receptor modulators (SERMs),
and calcitonin (19). Although estrogen
reduces the incidence of fractures and
colorectal cancer, it increases the inci-
dence of coronary artery disease, stroke,
breast cancer, and thromboembolic
events (20). An increased incidence of
uterine cancer is prevented by coadmin-
istration of progestins. Raloxifene, a
SERM which prevents bone loss and
fractures in postmenopausal women,
inhibits the growth of uterine tissue and
reduces the incidence of breast cancer
but increases the incidence of throm-
boembolic phenomena (19, 21). Calci-
tonin inhibits osteoclastic bone resorp-
tion, an effect mediated by calcitonin
receptors. However, calcitonin down-
regulates calcitonin receptors, and this
may reduce its effectiveness (19). Bis-
phosphonates act by inactivating osteo-
clasts to increase bone mineral density
and prevent fractures whereas long-
term treatment with bisphosphonates
produces microdamage accumulation
and increased susceptibility to fractures
in dogs (22). This potential complica-
tion of bisphosphonate therapy has not
been reported in patients with osteo-
porosis but could occur as a conse-
quence of inhibition of bone formation
rate and remains a concern (21).
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Figure 1
Regulation of osteoclast formation, function, and apoptosis by cytokines produced by bone
marrow stromal cells, osteoblasts, monocytes, T cells, and B cells. Stimulatory factors are
shown in orange and inhibitory factors in green. The effects of E to enhance (+) and inhibit
(–) the factors are shown in red.
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New drugs that are under investiga-
tion to treat bone-resorbtion diseases
include inhibitors of αvβ3 integrin, an
adhesion receptor that mediates
attachment of osteoclasts to bone sur-
face (5, 19), and OPG. Indeed, in dose-
response studies lasting for two to
three months, single doses of OPG,
which inhibits both differentiation
and activation of osteoclasts, were
shown to profoundly inhibit bone
resorption in postmenopausal women
(23) and in patients with multiple
myeloma or skeletal metastases caused
by breast cancer (24).
Despite the breadth and depth of
these seminal discoveries, there is
still much more to be learned about
basic bone biology and the mecha-
nisms by which estrogen modulates
bone metabolism.
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Azathioprine: old drug, new actions
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A knowledge of the biochemical loci of
action of 6-MP in the inhibition of
nucleic acid synthesis is not sufficient to
explain the effects of the thiopurines on
the immune system.
—Gertrude B. Elion (Winner of
1988 Nobel Prize in Medicine for
“important principals of drug
development”; codiscovered 6-MP
and azathioprine with George
Hitchings) (1)
Azathioprine is among the oldest
pharmacologic immunosuppressive
agents in use today. Initially developed
as a long-lived prodrug of 6-mercap-
topurine (6-MP), it was quickly found
to have a more favorable therapeutic
index. It was soon found that 6-MP
could produce remissions in child-
hood acute leukemia (1), and later,
that azathioprine could prolong renal
allograft survival (2). Over the past 50
years, azathioprine has been used in
the treatment of hematologic malig-
nancies, rheumatologic diseases, solid
organ transplantation, and inflamma-
tory bowel disease.
The drug is a purine analog, and the
accepted mechanism of action is at the
level of DNA (1, 3). Both in vitro and in
vivo, azathioprine is metabolized to 
6-MP through reduction by glu-
tathione and other sulphydryl-con-
taining compounds and then enzy-
matically converted into 6-thiouric
acid, 6-methyl-MP, and 6-thioguanine
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